Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Rhizen Pharmaceuticals (Switzerland) | Researchclopedia

Back to institutions

Rhizen Pharmaceuticals (Switzerland)

La Chaux-de-Fondscompany

119

Works

2,162

Citations

22

h-index

Top Research Topics

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment PI3K/AKT/mTOR signaling in cancer

Top Researchers

Yoshikazu Inoue Fukujuji Hospital

632 works37,127 citationsh-index: 72

Recent Research

Bioconversion and Metabolic Fate of the <i>n</i>-1 Polyunsaturated Fatty Acids, 6,9,12,15- Hexadecatetraenoic (C16:4 <i>n</i>-1) and 8,11,14,17- Octadecatetraenoic (C18:4 <i>n</i>-1) Acids, in HepG2 Cells

Koki Sugimoto,Hideto Nishiguchi,et al.

20250 citations

Advanced Breast Cancer Therapies

Cutaneous lymphoproliferative disorders research

Cancer, Hypoxia, and Metabolism

Ion Channels and Receptors

Biochemical and Molecular Research

Lung Cancer Treatments and Mutations

Acute Lymphoblastic Leukemia research

CAR-T cell therapy research

PARP inhibition in cancer therapy

Osamu Tanaka Asahi University

1,158 works18,225 citationsh-index: 67

Xiaoyi Wei Shanghai Business School

362 works7,296 citationsh-index: 46

Hideki Yoshida St. Marianna University School of Medicine

340 works4,538 citationsh-index: 31

Kenji Mizutani Japan Tobacco (Japan)

163 works4,148 citationsh-index: 35

Dhanapalan Nagarathnam

67 works3,801 citationsh-index: 25

High productivity of oxylipin KODA using <i>E. coli</i> transformed with lipoxygenase and allene oxide synthase genes of <i>Lemna paucicostata</i>

Kazuteru Takagi,Mineyuki Yokoyama,et al.

20242 citations

Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.

Piotr J. Wysocki,Maciej Tadeusz Lubaś,et al.

20240 citations

Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study

Swaminathan P. Iyer,Auris Huen,et al.

202322 citations

Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.

Piotr J. Wysocki,Maciej Tadeusz Lubaś,et al.

20230 citations

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.

Tamta Makharadze,Ivane Kiladze,et al.

20233 citations